Clinical Trial Update: Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy [Phase 2, Phase 3]

View source ↗

Summary

A Phase II/III study evaluating WST09 (padeliporfin) for prostate cancer after radiation therapy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Padeliporfin (WST09) (padeliporfin)

Snippet

Sponsor: STEBA France | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: TERMINATED